Skip to search formSkip to main contentSkip to account menu

Risedronate

Known as: Risedronsäure, RISE, 1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate 
A synthetic pyridinyl bisphosphonate agent. Risedronate binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption… 
National Institutes of Health

Related topics

Related topics

12 relations

Narrower (4)

ActonelNE 58095risedronate sodiumrisedronate sodium 30 MG Oral Tablet
DiphosphonatesDrug AllergyEsophageal AchalasiaHypocalcemia

Broader (1)

risedronic acid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.
Highly Cited
2010
Highly Cited
2010
Unusual mid‐shaft fractures during long‐term bisphosphonate therapy
Background  Bisphosphonates are the most commonly prescribed medications for the treatment of osteoporosis. Although existing… 
Highly Cited
2009
Highly Cited
2009
Fluorescent Risedronate Analogues Reveal Bisphosphonate Uptake by Bone Marrow Monocytes and Localization Around Osteocytes In Vivo
Bisphosphonates are effective antiresorptive agents owing to their bone‐targeting property and ability to inhibit osteoclasts. It… 
Highly Cited
2009
Highly Cited
2009
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate
SummaryOne year of high-dose bisphosphonate (BPs) therapy in dogs allowed the increased accumulation of advanced glycation end… 
Highly Cited
2009
Highly Cited
2009
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Review
2008
Review
2008
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
BACKGROUND Osteoporosis is an abnormal reduction in bone mass and bone deterioration leading to increased fracture risk… 
Highly Cited
2005
Highly Cited
2005
Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells.
Highly Cited
2004
Highly Cited
2004
Osteoblast proliferation and maturation by bisphosphonates.
Highly Cited
1999
Highly Cited
1999
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
OBJECTIVE Risedronate, a new pyridinyl bisphosphonate, is a potent antiresorptive bone agent. This study examines the safety and… 
Highly Cited
1998
Highly Cited
1998
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
This double-blind, placebo-controlled study was undertaken to determine 1) the efficacy of oral risedronate for prevention of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)